Tryptamine Therapeutics
Kelowna
About Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp’s lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2024)
- Ticker: cnsx:TRYP
- Website: tryptherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/tryptamine-therapeutics-149175 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.